RAW264.7 cells were fixed with 4% paraformaldehyde, permeabilized with ice-cold methanol, and blocked with MinuteBlock Blocking Buffer (Affinibody, China)
This results in decreased synthesis of ECM components, significantly reducing abnormal collagen deposition in myocardial tissue and substantially reversing myocardial hypertrophy and fibrosis (Chen et al., 2011)
As a reference, Selank is used clinically in Russia for therapy in GAD as 0.15% nasal drops
Ongoing assessment allows for the refinement of dosage to maximize results while ensuring patient safety
Summary Keywords Alzheimers disease, clinical trial, cognitive dysfunction, GLP-1 receptor agonist, neuroinflammation, neuroprotection, semaglutide, vascular dementia Citation Alhowail AH, Al Mouslem AK, Almatrafi MA and Aldubayan MA (2026) Semaglutide in cognitive dysfunction: neuroprotective potential, clinical trial limitations, and a prevention-focused framework